Three in Ten Doses of Metformin Missed by Patients with Type 2 Diabetes


eMediNexus Admin    25 December 2017

Patients with type 2 diabetes are least likely to adhere to the most commonly prescribed medication for their disease, potentially because of its adverse-event profile, suggests new research published online in Diabetes, Obesity and Metabolism.

A review of almost 50 studies showed that patients did not take 30% of prescribed doses of metformin, compared with 23% of doses of sulfonylureas, such as gliclazide, and 20% of thiazolidinediones, such as pioglitazone. Newer dipeptidyl peptidase-4 (DPP-4) inhibitors, or gliptins, had higher adherence rates, with patients not taking just 10% to 20% of doses. Researchers noted that compared with metformin, adherence was better with sulfonylureas, at a mean difference in adherence of 10.6% across five studies, and with thiazolidinediones, at a mean difference of 11.3% across six studies.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.